Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423683 · ClinicalTrials.gov registry record · Phase 3
Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism
A Phase 3 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 64
- Enrollment target
NCT00423683: Clinical Trial Phase 3 study, sponsored by Northwell Health.
NCT00423683 is a Phase 3 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 64 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00423683, a Phase 3 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 64 participants
- Enrollment target
Study Summary
The development of clots is a potentially deadly complication in many cancer patients. The current optimal treatment is unknown. Evidence supporting the effectiveness of the use of Inferior Vena Caval Filters is lacking. This study will compare the two standard of care treatment options: anticoagulation with or without a inferior vena cava filter. The anticoagulation medication chosen will be Arixtra and it will be given once a day as an injection. Patients will be called at various intervals to monitor their signs and symptoms of new thromboembolisms.
Primary Outcome
Rates of VCF complications, bleeding, and recurrent or residual DVTs or PEs
Interventions
- DRUG Arixtra alone
- DEVICE Arixtra + filter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Why NCT00423683 stopped before completion
NCT00423683 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Arixtra alone is the first listed.
NCT00423683 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00423683 about?
NCT00423683 is a clinical study titled "Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism". The development of clots is a potentially deadly complication in many cancer patients. The current optimal treatment is unknown. Evidence supporting the effectiveness of the use of Inferior Vena Caval Filters is lacking. This study will compare the two standard of care treatment options: anticoagula...
What is the current status of trial NCT00423683?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 64 participants. The study started on 2007-01. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00423683?
The interventions under investigation include: Arixtra alone (DRUG), Arixtra + filter (DEVICE).
Who is sponsoring clinical trial NCT00423683?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00423683's enrollment target sits among peer trials
64 1799th of 2000 higher than 201 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia